Please assess the completion status of the following clinical trial:

Trial Title: Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of seasonal allergic rhinitis from grass pollen~* Normal electrocardiogram~* Moderate to severe response to approx. 1500 grass pollen grains/m3 after 2 hrs of exposure in challenge chamber~* Positive skin prick test for grass pollen at or within 12 months preceding screening visit~* Positive RAST (class 2 or higher) for timothy grass pollen and to rPhl p 1 + rPhl p 5 at or within 12 months preceding screening visit~Exclusion Criteria:~* Pregnant or lactating females~* Females with childbearing potential not using medically acceptable birth control~* Structural nasal abnormalities, nasal polyposis, history of frequent nosebleeds, recent nasal surgery or ongoing upper respiratory tract infection~* Any respiratory disease other than mild asthma controlled with occasional short acting beta agonists and normal lung function~* Current or recent participation in another clinical trial~* SIT for grass pollen allergy in the last two years prior to study~* Past or present disease, which may affect outcome of the trial, judged by investigator~* Autoimmune diseases, immune defects including immunosuppression, immune- complex immunopathies~* Suspected hypersensitivity to any ingredients of study medication~* Use of prohibited medication prior to screening and throughout study~* depot corticosteroids (12 weeks)~* oral corticosteroids (8 weeks)~* inhaled corticosteroids (4 weeks)~* Allergic symptoms at the time of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- BM32 low dose (Type: EXPERIMENTAL): 3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
- BM32 medium dose (Type: EXPERIMENTAL): 3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
- BM32 high dose (Type: EXPERIMENTAL): 3 subcutaneous injections of BM32 over a time span of 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 3 subcutaneous injections over a time span of 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).